8 results about "Diosmin" patented technology

The present invention relates to a method for producing diosmin in plants by reconstructing the diosmin biosynthetic pathway. Reconstructing the diosmin biosynthetic pathway by selecting optimal genes according to the present invention has the effect of enabling mass production of diosmin or a precursor thereof in plants, and therefore can be advantageously used for large-scale production of diosmin or a precursor thereof in the form of a gene expression cassette, a recombinant vector, a transformant, a transgenic plant, a method for producing a transgenic plant, or a method for producing diosmin or a precursor thereof.

This invention discloses a method for preparing diosmin impurity compounds and their application, relating to the field of pharmaceutical impurity preparation technology. The preparation method includes the following steps: S1, preparation of compound IM-1: compound SM-1 and a methylating agent are heated under alkaline conditions to obtain compound IM-1; S2, preparation of compound formula 1: compound IM-1 is added to an alcohol solution, and an inorganic base is added under stirring. After the addition is complete, the mixture is kept warm and stirred, then cooled to 15-20°C, and dilute hydrochloric acid is added dropwise until the pH reaches 6.5-7. The mixture is concentrated to obtain the crude product of formula 1, and finally purified by thin-layer chromatography to obtain the pure product of formula I. This product can be used as a reference standard for the quality control of diosmin raw material, which helps to obtain a higher quality product.

The invention discloses large-particle diosmin prepared based on a crystallization regulating agent and a method and application thereof, and relates to the technical field of diosmin synthesis, the method comprises the following steps: S1, dissolving diosmin in a sodium hydroxide aqueous solution, and adding hydrochloric acid to adjust the pH value of the solution to 10-11; s2, adding a crystallization regulator, namely polyvinylpyrrolidone, with the use amount of the crystallization regulator being 0.01%-0.1% of the weight of diosmin, stirring, and uniformly mixing; s3, hydrochloric acid is added, the pH value of a solution system is adjusted to be 6-7, stirring is conducted, diosmin is separated out, centrifugation and washing crystallization are conducted, crystals separated out after washing are dried, a large-particle diosmin finished product is obtained, the particle size of the obtained large-particle diosmin is increased by 2-4 times, the repose angle is optimized to be 30-35 degrees, and the large-particle diosmin is obviously superior to 40-45 degrees of a traditional technology, and the large-particle diosmin is obtained. The technical bottlenecks of small diosmin particle size and poor powder fluidity in the traditional process are effectively broken through.

The present invention belongs to the technical field of pharmaceuticals. Disclosed are a pharmaceutical composition for treating a TDP-43 proteinopathy, and a preparation method therefor and the use thereof. The pharmaceutical composition comprises at least one of each of compounds of class A and compounds of class B. The compounds of class A comprise at least one of sodium aescinate, a sodium aescinate derivative, hederagenin or a hederagenin derivative; and the compounds of class B comprise at least one of dehydrated icaritin, a dehydrated icaritin derivative, diosmin or a diosmin derivative. The pharmaceutical composition has a good therapeutic effect on the TDP-43 proteinopathy.

The invention opens up a brand new application field of the composition formed by the diosmin and the PD-1 inhibitor, and provides a potential, effective, safe and economical new treatment scheme for gastric cancer patients, especially patients intolerant or drug-resistant to traditional chemotherapy. The invention proves that diosmin can effectively and specifically inhibit the activity of NUAK1 kinase and further inhibit a Wnt / beta-catenin signal channel at the downstream of the NUAK1 kinase. The effect is directly shown as that the protein expression levels of key transcription factors TCF4 and LEF1 are remarkably reduced, so that the function of diosmin serving as a novel NUAK1 inhibitor is proved on the molecular mechanism level, and the tumor inhibition effect of the composition formed by diosmin and the PD-1 inhibitor is remarkably superior to that of the PD-1 inhibitor.

The invention relates to application of diosmin in preparation of a medicine for improving emotional symptoms of an IBS (Irritable Bowel Syndrome) patient. According to the application, the application range of the medicine diosmin which has been clinically approved and is suitable for treating various symptoms related to vein lymphatic insufficiency and various symptoms related to acute hemorrhoid attack is expanded to treatment of emotional symptoms of IBS patients for the first time; specifically, the invention provides a new application of diosmin in preparation of medicines for improving the emotional symptoms of IBS patients, breakthrough transformation of new use of old medicines is realized, and strict animal model experiments prove that diosmin can effectively improve the emotional symptoms of IBS model mice and IBS patients. Besides, as a clinically approved medicine, the safety, pharmacokinetics and dosage range of diosmin in a human body are fully verified, so that a solid foundation is provided for the diosmin to quickly enter a clinical test stage of emotional symptoms of IBS patients, the research and development period is remarkably shortened, and the transformation risk is reduced.

The present invention belongs to the technical field of pharmaceuticals. Disclosed are a pharmaceutical composition for treating a TDP-43 proteinopathy, and a preparation method therefor and the use thereof. The pharmaceutical composition comprises at least one of each of compounds of class A and compounds of class B. The compounds of class A comprise at least one of sodium aescinate, a sodium aescinate derivative, hederagenin or a hederagenin derivative; and the compounds of class B comprise at least one of dehydrated icaritin, a dehydrated icaritin derivative, diosmin or a diosmin derivative. The pharmaceutical composition has a good therapeutic effect on the TDP-43 proteinopathy.

The invention belongs to the technical field of medicines, and discloses a pharmaceutical composition for preventing or treating ventricular arrhythmia after myocardial ischemia-reperfusion, the pharmaceutical composition is composed of diosmin, etomoxazide and fluoxetine, and the mass ratio of diosmin to etomoxazide to fluoxetine is 1: 1: 1. Western blot proves that diosmin, etomagazide and fluoxetine can inhibit fatty acid oxidation protein. In-vitro and in-vitro heart electrophysiological experiments prove that the pharmaceutical composition can effectively reduce the susceptibility of ventricular arrhythmia after myocardial ischemia-reperfusion. TTC staining proves that the pharmaceutical composition can effectively reduce the myocardial injury area after myocardial ischemia reperfusion. Based on the regulation effect of the composition on the susceptibility of ventricular arrhythmia after myocardial ischemia-reperfusion, the clinical application of the composition to the ventricular arrhythmia after myocardial ischemia-reperfusion can be further developed.